MKI67 and neoplasm: Immunohistochemistry-based tumor assessment of Ki67 validated that the proliferation of Capan-1 tumors was restrained by either olaparib or JPI-547, with a slightly more pronounced effect observed with JPI-547 (Figure 1H).